International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Epithelial-myoepithelial carcinoma (EMC) is a rare neoplasm, first described in 1972 by Donath et al (1). EMC accounts for ~1% of epithelial salivary gland tumors, with the majority of cases of EMC arising in the parotid gland (2). Histologically, EMC is characterized by two types of cells arranged in well-defined tubules; epithelial cells in the inner layer and myoepithelial cells in the outer layer. EMC is always found clinically, and is occasionally identified by the patient or doctor as it commonly presents as a painless and slow growing neoplasm. In addition, the majority of patients have no complaints at the early stage. EMC is recognized to be a low-grade malignant tumor with a low metastasis rate and the primary treatment of EMC is to surgical excision (3). However, EMC arising in the hypopharynx has not previously been reported. The current study presents the first case in a 48-year-old male who exhibited no other symptoms with the exception of dysphagia for six months. The 2-cm-diameter mass was predominantly located in the left posterior wall of the hypopharynx, and the mass was histologically and immunohistochemically confirmed as EMC. The current study describes the treatment and outcomes of EMC in the hypopharynx and may provide useful information for future studies. Patient provided written informed consent.
A 48-year-old male was referred to the Digestive System Department due to a 6-month history of dysphagia in February, 2011. A video-fiber gastroscopy revealed a 2-cm-diameter mass in the left posterior wall of the hypopharynx. False vocal folds, vocal folds and piriform fossa were normal, as were the other portions of the upper aero-digestive tract. A biopsy showed a minor salivary glands tumor. Computed tomography (CT) of the neck revealed a contrast-enhanced mass in the hypopharynx. The patient underwent partial hypopharyngectomy with a left-side neck dissection under general anesthesia. The partial neck dissection revealed 20 lymph nodes that were negative for metastases. The present patient has shown no sign of recurrence or metastasis during the 27 months of follow-up.
Microscopically, the tumor cells were arranged in duct-like structures with an inner layer of ductal cells and an outer layer of clear cells (Fig. 1A). Immunohistochemically, the outer layer of clear cells stained positive for calponin, p63 protein, glial fibrillary acidic protein, S-100 protein and smooth muscle actin, which is consistent with a myoepithelial phenotype (Fig. 1B). The inner layer stained positive for cytokeratin and cytokeratin-7, which is consistent with an epithelial phenotype (Fig. 1C). The tumor cells were partially involved in the overlying pharyngeal epithelium, and induced necrosis and exfoliation (Fig. 1D). These features were consistent with EMC. In the minor region, the tumor was composed of variable sized ducts and nests, and the tumor cells were monomorphic in appearance, round to oval and had a moderate amount of eosinophilic to clear cytoplasm (Fig. 2).
EMC is a rare neoplasm and the majority of cases occur in the parotid gland, while a few arise in the nasal cavity, paranasal sinus, nasopharynx, subglottic region, trachea, bronchus, lung, lacrimal gland, submandibular gland, tongue base, palate and liver (3). The majority of patients are females in their fifth to eighth decades (4). To the best of our knowledge, this is the first case of EMC occurring in the hypopharynx. The patient was male and had a 6-month history of dysphagia, without any pain or hoarseness.
The diagnosis of EMC is based on conventional light microscopy and immunohistochemical testing. Histologically, the EMC tumor is determined by well-characterized tubules of two cell types. These are an outer mantle of larger myoepithelial cells with a clear cytoplasm that stains positive for calponin, p63 protein, glial fibrillary acidic protein, S-100 protein and smooth muscle actin, that are surrounding an inner lining of eosinophilic cuboidal epithelial cells stained positive for cytokeratin, cytokeratin-7 and epithelial membrane antigen (3,5). By contrast, in the present case, certain areas of the specimens only consisted of variable sized ducts and nests, the tumor cells were monomorphic in appearance, round to oval and had a moderate amount of eosinophilic to clear cytoplasm, without the characteristic bilayered tubules, but similar to the characteristics of polymorphous low-grade adenocarcinoma. Initially it was believed that the diagnosis was a hybrid carcinoma composed of EMC and polymorphous low-grade adenocarcinoma. Therefore, this may cause diagnostic difficulty and confusion with other neoplasms if there were no characteristic bilayered tubules in the sampled specimens.
EMC is believed to be a low-grade malignancy tumor (6), and the first choice of treatment for EMC in the salivary glands is wide-surgical excision with a clear margin (7). Fonseca and Soares (3) reported that the recurrence rate of EMC is between 35 and 40%, and that the metastatic rate is between 8.1 and 25%. In the present study, the patient underwent partial hypopharyngectomy with a left-side neck dissection under general anesthesia. The partial neck dissection revealed 20 lymph nodes that were negative for metastases, and the patient has shown no sign of recurrence or metastasis during the 27 months of follow-up, however, close and prolonged follow-up is required to evalate the prognosis of EMC in the hypopharynx. A study by Cho et al (8) showed that the mean interval between diagnosis and recurrence was 5 years (range, 1–19 years) and that the mean interval between diagnosis and metastasis was 15 years (range, 4–20 years).
In conclusion, the present study reports the first case of an EMC in the hypopharynx. The patient has shown no sign of recurrence or metastasis during the 27 months since the partial hypopharyngectomy. The results of the current study may aid in the prognosis of EMC.
|
Donath K, Seifert G and Schmiz R: Diagnosis and ultrastructure of the tubular carcinoma of salivary gland ducts. Epithelial-myoepithelial carcinoma of the intercalated ducts. Virchows Arch A Pathol Pathol Anat. 356:16–31. 1972.(In German). | |
|
Ellis GL and Auclair PL: Malignant epithelial tumors. Atlas of Tumor Pathology. 3rd edition. AFIP; Washington: pp. 337–343. 1996 | |
|
Fonseca I and Soares J: Epithelial-myoepithelial carcinoma. World Health Organization Classification of Head and Neck Tumours. Barnes L, Eveson JW, Reichart P, et al: 1st edition. IARC Press; Lyon: pp. 225–226. 2005 | |
|
Seethala RR, Barnes EL and Hunt JL: Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol. 31:44–57. 2007. View Article : Google Scholar | |
|
Cheuk W and Chan JK: Advances in salivary gland pathology. Histopathology. 51:1–20. 2007. View Article : Google Scholar | |
|
Senis-Segarra L, Sahuquillo-Arce E, Davo R, et al: Salivary gland epithelial-myoepithelial carcinoma: behaviour, diagnosis and treatment. Med Oral. 7:391–395. 2002.(In Spanish). | |
|
Witterick IJ, Noyek AM, Chapnik JS, et al: Observation of the natural history of a parotid epithelialmyoepithelial carcinoma of intercalated ducts. J Otolaryngol. 22:176–179. 1993.PubMed/NCBI | |
|
Cho KJ, el-Naggar AK, Ordonez NG, et al: Epithelial-myoepithelial carcinoma of the salivary glands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and HER-2/neu oncogene. Am J Clin Pathol. 103:432–437. 1995. |